Who owns XILIO THERAPEUTICS INC?
- CUSIP Number: 98422t209
Tip: Access positions for across all investors
Analyze quarterly positions in Xilio Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Xilio Therapeutics stock
Who bought or sold XILIO THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors | 664k | $5.6M | 100% | Mar 2026 |
|
| Frazier Life Sciences Management | 423k | $3.6M | 100% | Mar 2026 |
|
| Vanguard Capital Management | 124k | $1.0M | 100% | Mar 2026 |
|
| Merck & Co | 106k | $891k | 100% | Mar 2026 |
|
| Morgan Stanley | 58k | $484k | 100% | Mar 2026 |
|
| AJU IB Investment | 48k | $401k | 100% | Mar 2026 |
|
| Geode Capital Management | 37k | $313k | 100% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 29k | $240k | 100% | Mar 2026 |
|
| GSA Capital Partners | 17k | $143k | 100% | Mar 2026 |
|
| Ghisallo Capital Management | 14k | $116k | 100% | Mar 2026 |
|
| UBS Group | 4.0k | $34k | 100% | Mar 2026 |
|
| Vanguard Global Advisers | 210.00 | $1.8k | 100% | Mar 2026 |
|
| Royal Bank of Canada | 91.00 | $999.999000 | 100% | Mar 2026 |
|
| Key FInancial | 59.00 | $496.001200 | 100% | Mar 2026 |
|